Fiche centre
Sunnybrook Health Sciences Centre
Toronto — Canada
Essais liés25clinical trials
VilleTorontolocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02464761
Essais cliniques associés
25| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Stentrode | Sclérose latérale amyotrophique | Non applicable | NCT07446114 | FOCUS-CAN — Functional Outcomes and Control Using Synchron BCI - Canada | TERMINATED |
| Nabilone | Alzheimer | Phase 3 | NCT04516057 | NAB-IT — Nabilone for Agitation Blinded Intervention Trial | RECRUITING |
| Edoxaban 15 mg | Accident vasculaire cérébral | Phase 3 | NCT07454707 | Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial | RECRUITING |
| Physiology-guided NCL PCI | Maladie coronarienne | Non applicable | NCT05701358 | COMPLETE-2 — Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease | ACTIVE_NOT_RECRUITING |
| Tofersen | Sclérose latérale amyotrophique | Phase 3 | NCT04856982 | ATLAS — Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | ACTIVE_NOT_RECRUITING |
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| WATCHMAN FLX LAAC Device | Accident vasculaire cérébral | Non applicable | NCT04394546 | CHAMPION-AF Clinical Trial | ACTIVE_NOT_RECRUITING |
| Visudyne | Cancer | Phase 1 | NCT02464761 | Photodynamic Therapy for the Treatment of Vertebral Metastases | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT03599245 | This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) | COMPLETED |
| Monoplace Hyperbaric Chamber (Class III medical device). | Myopathies | Non applicable | NCT06082518 | PCS-HBOT — Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments | ACTIVE_NOT_RECRUITING |
| Inavolisib | Cancer | Phase 3 | NCT06790693 | INAVO123 — A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| NB-4746 High dose | Sclérose latérale amyotrophique | Phase 1/2 | NCT07369076 | A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. | RECRUITING |
| CBD | Alzheimer | Phase 2 | NCT06014424 | CALM-IT — Cannabidiol Medication Intervention Trial | RECRUITING |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| Floxuridine (FUDR) | Cancer | Phase 2 | NCT07764497 | HAIP-6192 — Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis | RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| Next Generation Dome Helmet Focused Ultrasound | Sclérose latérale amyotrophique | Phase 1 | NCT07193953 | ALSFUS003 — Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07170150 | TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT07191145 | Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | RECRUITING |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |
| Perindopril | Alzheimer | Phase 2 | NCT02085265 | Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients | TERMINATED |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| The Ontario Neurodegenerative Disease Research Initiative | Sclérose latérale amyotrophique | À vérifier | NCT04104373 | The Ontario Neurodegenerative Disease Research Initiative | COMPLETED |